RBC Capital raised the firm’s price target on Ligand (LGND) to $155 from $143 and keeps an Outperform rating on the shares. The firm cites the ...

Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in ...

Reports Q4 revenue $42.8M, consensus $39.03M. “We achieved significant revenue growth in 2024 driven by strong momentum across our major ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

Novel protein cage systems can control and visualize orientational changes in aromatic side chains upon ligand binding, as ...

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is expected to announce its earnings results before the market opens ...

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $31.1 million in its fourth quarter. On a per-share basis, the Jupiter, Florida ...

FMS-like tyrosine kinase 3 ligand (FLT3LG), also known as FL, Flt3L, and FLT3LG, is an α-helical cytokine crucial for the differentiation of multiple hematopoietic cell lineages. It is expressed ...

On a per-share basis, the Jupiter, Florida-based company said it had a loss of $1.64. The drugmaker posted revenue of $42.8 million in the period, which topped Street forecasts. Three analysts ...